SCHEMBL3085558

SCHEMBL3085558

N#Cc1c(F)cccc1C(O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 4/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CES2 O00748 3/20 0.38
CES1 P23141 3/20 0.38
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
TAS1R2 Q8TE23 1/20 0.35
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
HRH1 P35367 1/20 0.35
ADORA1 P30542 2/20 0.34
ADORA2A P29274 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
MAPK10 P53779 1/20 0.33
TRPV4 Q9HBA0 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13058538 0.80 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDHSD17B10DRD2
SCHEMBL186269 0.78 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDHSD17B10CES2
SCHEMBL16952797 0.77 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDHSD17B10TAS1R3
SCHEMBL3154084 0.77 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDHSD17B10CES2
SCHEMBL16953974 0.77 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDHSD17B10CES2
SCHEMBL16960357 0.76 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDHSD17B10TAS1R3
SCHEMBL26464557 0.74 ALDH1A1 (0.48) ALDH1A1KDM4EHPGDHSD17B10DRD2
SCHEMBL16950993 0.74 ALDH1A1 (0.44) ALDH1A1KDM4EHPGDHSD17B10TAS1R3
Cyanide SCHEMBL28871133 0.73 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDHSD17B10TAS1R3
SCHEMBL1154516 0.73 ALDH1A1 (0.44) ALDH1A1HPGDCES2CES1TAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114948-B1 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE ABBVIE INC (US) 2014-06-25 EP disclosed
US-7790721-B2 Pyrroloquinoxalinone inhibitors of poly(ADP-ribose)polymerase ABBOTT LABORATORIES (US) 2010-09-07 US disclosed
EP-2114948-A2 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE Abbott Laboratories (US) 2009-11-11 EP disclosed
WO-2008082887-A2 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE ABBOTT LABORATORIES (US) 2008-07-10 WO disclosed
US-20080161292-A1 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE ABBOTT LABORATORIES (US) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161292-A1 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE PARP1, PARP2, PARP3 ALDH1A1 1358/4885KDM4E 4026/4885HPGD 518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.